Addiction - Articles - Page 8 | CARLAT PUBLISHING

Treating Addiction in Patients Transitioning to/from Incarceration

August 1, 2019

Karen Cropsey, PsyD

Conatser Turner Endowed Professor of Psychiatry, University of Alabama at Birmingham.

Dr. Cropsey has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Addiction treatment during incarceration is limited, and release from incarceration presents its own set of challenges. In this QA interview, Dr. Karen Cropsey discusses effective treatment options for patients with substance use disorders transitioning to or from incarceration.

New Generic Versions of Naloxone

August 1, 2019

Talia Puzantian, PharmD, BCPP.

Talia Puzantian, PharmD, BCPP. Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Naloxone, a rescue medication effective for reversing opioid overdose, will soon be available in two generic forms for layperson use. This news of note summarizes these generic, lower-cost products.

Opioid Use Disorder: Is There an App for That?

August 1, 2019

Joshua Sonkiss, MD.

Joshua Sonkiss, MD. Dr. Sonkiss has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This News of Note discusses the first FDA-approved mobile app for SUDs, called reSET-O. Classified as a mobile medical app (MMAs), reSET-O can be used as an adjunct to outpatient opioid use disorder treatment. Unlike most apps, reSET-O requires a prescription to unlock and use.

Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 randomized, double-blind, placebo- controlled trial study casts doubt on using gabapentin enacarbil extended-release (GE-XR) (Horizant), an extended-release version of gabapentin, for treatment in patients with alcohol use disorder

Can Buprenorphine Improve PTSD Symptoms?

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 retrospective study examines the potential benefits of using buprenorphine/naloxone to treat co-occurring PTSD and opioid use disorder.

Assessment of Patients with Chronic Pain and Addiction

June 2, 2019

It can be challenging to manage chronic pain, even more so when our patients suffer from addiction, says Michael McGee, MD, Chief Medical Officer, The Haven at Pismo, Avila Beach, CA. We can find ourselves walking a tightrope between the risk of relapse due to the inadequate treatment of pain,...

A Primer on Drug Screening Methods

May 27, 2019

Specimens of urine, blood, hair, saliva, sweat and even nails can be used to drug test. Some are more specific, sensitive and accurate than others, says Talia Puzantian, PharmD, BCCP, who goes over the following drug testing methods in The Carlat Addiction Treatment Report:Urine screening is noninvasive and the most-common...

Coffee: Healthy Study Aid or the Addiction We Hate to Acknowledge?

January 1, 2019

Rehan Aziz, MD.

Rehan Aziz, MD. Associate professor of psychiatry and neurology, Rutgers Robert Wood Johnson School of Medicine. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Caffeine permeates our society. It comes in many forms, including coffee and increasingly popular energy drinks. We consume it, and so do our patients. So, is it a harmless habit or a potentially harmful addiction? Let’s take a sip and find out.

Note From the Editor-in-Chief

October 1, 2018

Bachaar Arnaout, MD

Bachaar Arnaout, MD Editor-in-Chief

Addiction spares no age group, but it often goes undetected in older adults age 65 or older, and its treatment poses age-specific challenges.

Alcohol Use Disorder Meds in Older Adults

October 1, 2018

Rehan Aziz, MD, FAPA

Rehan Aziz, MD, FAPA Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How should we employ pharmacotherapies for alcohol use disorder (AUD) in older adult patients? There are three FDA-approved medications (acamprosate, disulfiram, and naltrexone) and two other commonly used off-label agents (gabapentin and topiramate).